Beijing Centre Biology is a technology company.
Beijing Centre Biology has raised $10.0M across 2 funding rounds.
Beijing Centre Biology has raised $10.0M in total across 2 funding rounds.
Beijing Centre Biology is a high-technology company specializing in the research, development, manufacturing, and promotion of animal health care products, primarily operating within the pharmaceuticals and animal drug sectors. It serves the veterinary and animal health markets by providing natural and innovative solutions for animal disease prevention and treatment, including animal train control and monitoring systems (TCMs). The company addresses challenges such as chronic inflammatory diseases in animals and aims to improve animal health and welfare. With a workforce of approximately 1,900 employees and revenues estimated under $5 million, Beijing Centre Biology demonstrates steady growth momentum in the animal health industry[1][2][3][5].
Founded in 1999 and headquartered in Beijing, China, Beijing Centre Biology emerged from a focus on integrating traditional Chinese herbal medicine with modern veterinary science. The founders leveraged expertise in both biotechnology and traditional medicine to develop natural animal health products that offer alternatives to conventional pharmaceuticals, which often have side effects or high costs. Early traction came from successful product launches and research publications demonstrating efficacy in treating conditions like canine atopic dermatitis and improving fish health, which helped establish credibility in the veterinary pharmaceutical market[3][4].
Beijing Centre Biology rides the growing global trend toward sustainable and natural animal health solutions, driven by increasing concerns over antibiotic resistance, animal welfare, and environmental impact. The timing is favorable as regulatory bodies and consumers push for safer, more natural veterinary products. The company’s integration of traditional herbal medicine with modern biotech aligns with a broader movement in life sciences toward combining ancient knowledge with cutting-edge science. This positions Beijing Centre Biology as a key player influencing the veterinary pharmaceutical ecosystem in China and potentially beyond, contributing to innovation in animal health care and disease management[2][4][5].
Looking ahead, Beijing Centre Biology is poised to expand its product portfolio and deepen its research capabilities, potentially increasing its market share in the animal health sector. Trends such as precision veterinary medicine, digital monitoring of animal health, and natural product demand will likely shape its growth trajectory. The company’s ability to blend traditional medicine with modern technology could enhance its influence, making it a notable innovator in sustainable animal health solutions. Continued investment in R&D and strategic partnerships will be critical for scaling its impact and navigating competitive pressures in the pharmaceutical and animal health industries[4][5].
Beijing Centre Biology has raised $10.0M in total across 2 funding rounds.
Beijing Centre Biology's investors include Qiming Venture Partners.
Beijing Centre Biology has raised $10.0M across 2 funding rounds. Most recently, it raised $3.0M Series B in June 2012.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2012 | $3.0M Series B | Qiming Venture Partners | |
| Aug 1, 2011 | $7.0M Series A | Qiming Venture Partners |